Because PAX5 mutations in B-ALL are usually monoallelic, enhancing wild-type PAX5 allele function to overcome its haploinsufficiency represents a promising strategy for B-ALL treatment. The gene discussed is PAX5; the disease is acute lymphoblastic leukemia.